A5013393910- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Advanced Drug Delivery Systems
- Radiopharmaceutical Chemistry and Applications
- Protein purification and stability
- Neuroinflammation and Neurodegeneration Mechanisms
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Nanoparticle-Based Drug Delivery
- Synthesis and Biological Evaluation
- Enzyme Catalysis and Immobilization
- Glycosylation and Glycoproteins Research
- Electrohydrodynamics and Fluid Dynamics
- Nanofabrication and Lithography Techniques
- Multiple Sclerosis Research Studies
- Complement system in diseases
- Bacterial biofilms and quorum sensing
- Attention Deficit Hyperactivity Disorder
- Biochemical Analysis and Sensing Techniques
- Inhalation and Respiratory Drug Delivery
- RNA Interference and Gene Delivery
- Neurotransmitter Receptor Influence on Behavior
- Cancer Genomics and Diagnostics
- Transgenic Plants and Applications
University College London
2022-2024
Universitätsmedizin Göttingen
2019
Pieris Pharmaceuticals (United States)
2016
Data Harbor (United States)
2015
University of Würzburg
2010
Chronic infections of Candida albicans are characterised by the embedding budding and entwined filamentous fungal cells into biofilms. The biofilms refractory to many drugs associated with ocular infections. objective was test activity nanoparticulate amphotericin B (AmB) against biofilms.AmB encapsulated in Molecular Envelope Technology (MET, N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan) nanoparticles tested vitro. Confocal laser scanning microscopy (CLSM)...
Levodopa (L-DOPA) is an oral Parkinson's Disease drug that generates the active metabolite - dopamine (DA) in vivo. However, L-DOPA exhibits low bioavailability, limited brain uptake, peripheral DA-mediated side effects and its poor bioavailability can lead to long-term complications. Here we show forms stable (for at least 5 months) 300 nm nanoparticles when encapsulated within N-palmitoyl-N-monomethyl-N,N-dimethyl-N,N,N-trimethyl-6-O-glycolchitosan (GCPQ). A nano-in-microparticle...
Teriparatide (and analogue peptides) are the only FDA approved anabolic treatments for osteoporosis. Current therapies administered as a daily subcutaneous injection, which limits patient adherence and clinical efficacy. To achieve desired effect, controlled delivery system must ensure pulsatile release profile over prolonged period. Thermo-responsive formulations (e.g. liposomes) can undergo temperature-related phase-transition allow active control of drug release. Herein, thermo-responsive...
Electrospraying is a processing technique that has gained much interest to prepare polymeric particles. The operates at ambient temperature, thereby avoiding heat induced degradation of labile therapeutics (e.g. peptides and proteins). Exposure organic solvents can be minimised by co-axial electrospraying through separation core (aqueous) shell (organic) solvents. However, aqueous solutions are often difficult electrospray due high surface tension. Immiscibility between the core-shell...
Meeting abstracts CD137 is a potent costimulatory immunoreceptor and member of the TNF-receptor (TNFR) superfamily. The receptor, also known as 4-1BB, mainly expressed on activated CD4+ CD8+ T cells, B natural killer (NK) cells. While multiple lines evidence show
Abstract Background. CD137 (4-1BB) is a key costimulatory immunoreceptor and member of the TNF-receptor (TNFR) superfamily. While multiple lines evidence show that highly promising therapeutic target in cancer, current mAb-based approaches are not designed to achieve tumor-target driven activation may display toxicity limited window due peripheral T cell NK activation. To overcome this limitation, we generated PRS-343, HER2/CD137 bispecific promote clustering by bridging CD137-positive cells...
The authors did not submit an updated abstract. original abstract should be considered final. Citation Format: Sarina Piha-Paul, Johanna C. Bendell, Anthony Tolcher, Rachna Shroff, Paula R. Pohlmann, Sara A. Hurvitz, Anuradha Krishnamurthy, Naimish Pandya, Shane Olwill, Markus Zettl, Kayti Aviano, Lynn Mar, Patrick Jolicoeur, Aizea Morales Kastresana, Corinna Schlosser, Ingmar Bruns, Alice Bexon, Geoffrey Y. Ku. Clinical and biomarker activity of PRS-343, a bispecific fusion protein...
Abstract Background. 4-1BB (CD137) is a key costimulatory immunoreceptor and highly promising therapeutic target in cancer. To overcome toxicity efficacy limitations of current targeting antibodies, we have developed PRS-343, 4-1BB/HER2 bispecific based on Anticalin® technology. We previously reported the generation characterization PRS-343 with regard to preclinical proof-of-concept basic drug-like properties.1 Here, describe dataset supporting initiation first-in-patient trial. Methods...
Therapeutic proteins and peptides are clinically important, offering potency while reducing the potential for off-target effects. Research interest in developing therapeutic polypeptides has grown significantly during last four decades. However, despite growing research effort, maintaining stability of throughout their life cycle remains a challenge. Electrohydrodynamic (EHD) techniques have been widely explored encapsulation delivery many biopharmaceuticals. In this work, we monoaxial...
Background: Increasing evidence shows that 4-1BB is a key costimulatory immunoreceptor and highly-promising therapeutic target in cancer. Current antibody-based approaches showed immune cell activation not only tumor tissues, but also the periphery, which associated with dose-limiting on-target toxicity. To overcome this limitation, we generated PRS-342, GPC3/4-1BB bispecific molecule based on Anticalin technology. This designed to promote clustering by bridging 4-1BB-positive T cells...
Abstract Background: CD137 (4-1BB) is a key costimulatory immunoreceptor and member of the TNF-receptor (TNFR) superfamily. While multiple lines evidence show that highly promising therapeutic target in cancer, current mAb-based approaches are not designed to achieve tumor-target driven activation may display toxicity limited window due peripheral T cell NK activation. To overcome this limitation, we generated PRS-343, CD137/HER2 bispecific promote clustering by bridging CD137-positive cells...
Abstract Background: Increasing evidence shows that 4-1BB is a key costimulatory immunoreceptor and highly-promising therapeutic target in cancer. Current antibody-based approaches showed immune cell activation not only tumor tissues, but also the periphery, which associated with dose-limiting on-target toxicity. To overcome this limitation, we generated PRS-342, GPC3/4-1BB bispecific molecule based on Anticalin technology. This designed to promote clustering by bridging 4-1BB-positive T...
Abstract Background: CD137 is a potent costimulatory immunoreceptor and member of the TNF-receptor (TNFR) superfamily. The receptor, also known as 4-1BB, mainly expressed on activated CD4+ CD8+ T cells, B natural killer (NK) cells. While multiple lines evidence show that highly promising therapeutic target, current approaches are not designed to achieve tumor-target driven activation, which may reduce available window via peripheral cell activation toxicity. To overcome this limitation, we...
Abstract CD137 is a potent costimulatory immunoreceptor and member of the TNF-receptor (TNFR) superfamily. The receptor, also known as 4-1BB, mainly expressed on activated CD4+ CD8+ T cells, B natural killer (NK) cells. While multiple lines evidence show that highly promising therapeutic target, current approaches using monospecific antibodies may display limited window due to peripheral cell NK activation, leading unwanted toxicity. To overcome this limitation, we have generated bispecific...
<div>AbstractPurpose:<p>4-1BB (CD137) is a key costimulatory immunoreceptor and promising therapeutic target in cancer. To overcome limitations of current 4-1BB–targeting antibodies, we have developed PRS-343, 4-1BB/HER2 bispecific molecule. PRS-343 designed to facilitate T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering activation.</p>Experimental Design:<p>PRS-343 was generated the genetic fusion 4-1BB–specific Anticalin proteins variant...
<div>AbstractPurpose:<p>4-1BB (CD137) is a key costimulatory immunoreceptor and promising therapeutic target in cancer. To overcome limitations of current 4-1BB–targeting antibodies, we have developed PRS-343, 4-1BB/HER2 bispecific molecule. PRS-343 designed to facilitate T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering activation.</p>Experimental Design:<p>PRS-343 was generated the genetic fusion 4-1BB–specific Anticalin proteins variant...